Cantor Fitzgerald Comments on AQST FY2026 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Aquestive Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($0.81) per share for the year. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million.

AQST has been the subject of a number of other reports. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, May 15th. Lake Street Capital reduced their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Alliance Global Partners reaffirmed a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They set an "outperform" rating and a $7.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Price Performance

NASDAQ:AQST traded down $0.14 during midday trading on Wednesday, reaching $3.27. 769,853 shares of the company traded hands, compared to its average volume of 1,535,702. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $5.80. The company has a fifty day moving average price of $2.73 and a 200 day moving average price of $3.11. The firm has a market capitalization of $324.80 million, a price-to-earnings ratio of -7.27 and a beta of 1.94.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AQST. Summit Wealth & Retirement Planning Inc. acquired a new position in Aquestive Therapeutics during the 1st quarter worth about $29,000. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the first quarter worth about $31,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Aquestive Therapeutics in the first quarter worth approximately $33,000. New York State Common Retirement Fund raised its holdings in Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $44,000. Institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.